

# China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Research Report 2018

<https://marketpublishers.com/r/CE308C940ADQEN.html>

Date: March 2018

Pages: 95

Price: US\$ 3,400.00 (Single User License)

ID: CE308C940ADQEN

## Abstracts

The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

China plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of xx%.

This report studies the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics development status and future trend in China, focuses on top players in China, also splits Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include

Astellas

Johnson & Johnson

Sanofi

Dendreon.

Bayer

Geographically, this report splits the China market into six regions,

South China

East China

Southwest China

Northeast China

North China

Central China

Northwest China

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

Hormonaltherapy

Chemotherapy

Immunotherapy

Radiotherapy

On the basis of the end users/application, this report covers

Prostate Cancer

Others

If you have any special requirements, please let us know and we will offer you the report as you want.

## Contents

China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market  
Research Report 2018

### **1 CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS OVERVIEW**

1.1 Product Overview and Scope of Castration-Resistant Prostate Cancer  
(CRPC)/HRPCA Therapeutics

1.2 Classification of Castration-Resistant Prostate Cancer (CRPC)/HRPCA  
Therapeutics by Product Category

1.2.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales  
(K Units) Comparison by Type (2013-2025)

1.2.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales  
(K Units) Market Share by Type in 2017

1.2.3 Hormonaltherapy

1.2.4 Chemotherapy

1.2.5 Immunotherapy

1.2.6 Radiotherapy

1.3 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market  
by Application/End Users

1.3.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales  
(K Units) and Market Share Comparison by Applications (2013-2025)

1.3.2 Prostate Cancer

1.3.3 Others

1.4 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market  
by Region

1.4.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics  
Market Size (Million USD) Comparison by Region (2013-2025)

1.4.2 South China Castration-Resistant Prostate Cancer (CRPC)/HRPCA  
Therapeutics Status and Prospect (2013-2025)

1.4.3 East China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics  
Status and Prospect (2013-2025)

1.4.4 Southwest China Castration-Resistant Prostate Cancer (CRPC)/HRPCA  
Therapeutics Status and Prospect (2013-2025)

1.4.5 Northeast China Castration-Resistant Prostate Cancer (CRPC)/HRPCA  
Therapeutics Status and Prospect (2013-2025)

1.4.6 North China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Status and Prospect (2013-2025)

1.4.7 Central China Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Status and Prospect (2013-2025)

1.5 China Market Size (Sales and Revenue) of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics (2013-2025)

1.5.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) (2013-2025)

1.5.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (%) (2013-2025)

## **2 CHINA CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS MARKET COMPETITION BY PLAYERS/MANUFACTURERS**

2.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales and Market Share of Key Players/Manufacturers (2013-2018)

2.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Share by Players/Manufacturers (2013-2018)

2.3 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Average Price (USD/Unit) by Players/Manufacturers (2013-2018)

2.4 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Competitive Situation and Trends

2.4.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Concentration Rate

2.4.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share of Top 3 and Top 5 Players/Manufacturers

2.4.3 Mergers & Acquisitions, Expansion in China Market

2.5 China Players/Manufacturers Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Manufacturing Base Distribution, Sales Area, Product Types

## **3 CHINA CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS SALES AND REVENUE BY REGION (2013-2018)**

3.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Market Share by Region (2013-2018)

3.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Market Share by Region (2013-2018)

3.3 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Price (USD/Unit) by Regions (2013-2018)

## **4 CHINA CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS SALES AND REVENUE BY TYPE/ PRODUCT CATEGORY (2013-2018)**

4.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Market Share by Type/ Product Category (2013-2018)

4.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Market Share by Type (2013-2018)

4.3 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Price (USD/Unit) by Type (2013-2018)

4.4 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Growth Rate (%) by Type (2013-2018)

## **5 CHINA CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS SALES BY APPLICATION (2013-2018)**

5.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Market Share by Application (2013-2018)

5.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Growth Rate (%) by Application (2013-2018)

5.3 Market Drivers and Opportunities

## **6 CHINA CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS PLAYERS/SUPPLIERS PROFILES AND SALES DATA**

### **6.1 Astellas**

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

6.1.4 Main Business/Business Overview

### **6.2 Johnson & Johnson**

6.2.1 Company Basic Information, Manufacturing Base and Competitors

6.2.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

6.2.4 Main Business/Business Overview

6.3 Sanofi

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

6.3.4 Main Business/Business Overview

6.4 Dendreon.

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Dendreon. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

6.4.4 Main Business/Business Overview

6.5 Bayer

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

6.5.4 Main Business/Business Overview

## **7 CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS MANUFACTURING COST ANALYSIS**

## 7.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

## 7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

## 7.3 Manufacturing Process Analysis of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

# **8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

## 8.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Manufacturers in 2017

8.4 Downstream Buyers

# **9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

## 9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

## 9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

## 9.3 Distributors/Traders List

# **10 MARKET EFFECT FACTORS ANALYSIS**

## 10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

## **11 CHINA CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS MARKET SIZE (SALES AND REVENUE) FORECAST (2018-2025)**

11.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD) Forecast (2018-2025)

11.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) Forecast by Type (2018-2025)

11.3 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) Forecast by Application (2018-2025)

11.4 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) Forecast by Region (2018-2025)

## **12 RESEARCH FINDINGS AND CONCLUSION**

## **13 METHODOLOGY AND DATA SOURCE**

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

13.4 Author List

The report requires updating with new data and is sent in 2-3 business days after order is placed.



## List Of Tables

### LIST OF TABLES AND FIGURES

- Figure Global and China Market Size (Million USD) Comparison (2013-2025)
- Table Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Revenue (Million USD) Market Split by Product Type
- Table Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) by Application (2013-2025)
- Figure Product Picture of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
- Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) Comparison by Types (Product Category) (2013-2025)
- Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Volume Market Share by Types in 2017
- Figure Hormonaltherapy Product Picture
- Figure Chemotherapy Product Picture
- Figure Immunotherapy Product Picture
- Figure Radiotherapy Product Picture
- Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) Comparison by Application (2013-2025)
- Figure China Sales Market Share (%) of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Application in 2017
- Figure Prostate Cancer Examples
- Table Key Downstream Customer in Prostate Cancer
- Figure Others Examples
- Table Key Downstream Customer in Others
- Figure South China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2013-2025)
- Figure East China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2013-2025)
- Figure Southwest China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2013-2025)
- Figure Northeast China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2013-2025)
- Figure North China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2013-2025)
- Figure Central China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (2013-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) (2013-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate (%) (2013-2025)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales of Key Players/Manufacturers (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Share (%) by Players/Manufacturers (2013-2018)

Figure 2017 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Share (%) by Players/Manufacturers

Figure 2017 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Share (%) by Players/Manufacturers

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Players/Manufacturers (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) by Players/Manufacturers (2013-2018)

Figure 2017 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) by Players/Manufacturers

Figure 2017 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) by Players/Manufacturers

Table China Market Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Average Price of Key Players/Manufacturers (2013-2018)

Figure China Market Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Average Price of Key Players/Manufacturers in 2017

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share of Top 3 Players/Manufacturers

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share of Top 5 Players/Manufacturers

Table China Players/Manufacturers Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Manufacturing Base Distribution and Sales Area

Table China Players/Manufacturers Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Category

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) by Regions (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Share (%) by Regions (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Share (%) by Regions (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

Market Share (%) by Regions in 2017

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Market Share by Regions (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) by Regions (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) by Regions (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) by Regions in 2017

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Price (USD/Unit) by Regions (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) by Type (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Share (%) by Type (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Share (%) by Type (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) by Type in 2017

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Market Share by Type (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) by Type (2013-2018)

Figure Revenue Market Share of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Type (2013-2018)

Figure Revenue Market Share of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Type in 2017

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Price (USD/Unit) by Types (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Growth Rate (%) by Type (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) by Applications (2013-2018)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) by Applications (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) by Application (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) by Application in 2017

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Growth Rate (%) by Application (2013-2018)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Growth Rate (%) by Application (2013-2018)

Table Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Basic Information List

Table Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

Figure Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) (2013-2018)

Figure Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) in China (2013-2018)

Figure Astellas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) in China (2013-2018)

Table Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Basic Information List

Table Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

Figure Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) (2013-2018)

Figure Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) in China (2013-2018)

Figure Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) in China (2013-2018)

Table Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Basic Information List

Table Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

Figure Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) (2013-2018)

Figure Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) in China (2013-2018)

Figure Sanofi Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) in China (2013-2018)

Table Dendreon. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Basic Information List

Table Dendreon. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

Figure Dendreon. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) (2013-2018)

Figure Dendreon. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) in China (2013-2018)

Figure Dendreon. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) in China (2013-2018)

Table Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Basic Information List

Table Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2013-2018)

Figure Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) (2013-2018)

Figure Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share (%) in China (2013-2018)

Figure Bayer Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share (%) in China (2013-2018)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Figure Manufacturing Process Analysis of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Figure Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Industrial Chain Analysis

Table Raw Materials Sources of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Players/Manufacturers in 2017

Table Major Buyers of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Table Distributors/Traders List

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales (K Units) and Growth Rate (%) Forecast (2018-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) and Growth Rate Forecast (2018-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Price (USD/Unit) Trend Forecast (2018-2025)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

(K Units) Forecast by Type (2018-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

(K Units) Forecast by Type (2018-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

Volume Market Share Forecast by Type in 2025

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

(K Units) Forecast by Application (2018-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

Volume Market Share Forecast by Application (2018-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

Volume Market Share Forecast by Application in 2025

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

(K Units) Forecast by Regions (2018-2025)

Table China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

Volume Share Forecast by Regions (2018-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

Volume Share Forecast by Regions (2018-2025)

Figure China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales

Volume Share Forecast by Regions in 2025

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

## I would like to order

Product name: China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Research Report 2018

Product link: <https://marketpublishers.com/r/CE308C940ADQEN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CE308C940ADQEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

